Close Menu

Mayo Medical Laboratories

Mayo Medical Laboratories said this week that it has begun offering mass spec-based serum thyroglobulin testing using SISCAPA technology.

The Mayo Medical Laboratories will now offer Sequenom's MaterniT21 Plus test to patients at high risk for fetal chromosome abnormalities.

BioTheranostics said this week that Mayo Clinic and Mayo Medical Laboratories will offer the company's CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.

NEW YORK (GenomeWeb News) – Mayo Clinic and Mayo Medical Laboratories will offer BioTheranostics' CancerType ID molecular cancer classification test under a deal announced today.

The new test will be based on real-time PCR using fluorescence resonance energy transfer probes for detection.

The technology will allow Mayo to offer a test for M. tuberculosis complex speciation.

The eventual goal of the partnership would be to port the validated assay onto Rheonix's fully automated, modular molecular testing platform, which is still under development but may reduce the complexity and cost of warfarin sensitivity testing.

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.